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Abstract
Carbapenem-resistant or intermediate (MIC ‡1 mg/L) clinical
isolates (n = 12) of three species of Enterobacteriaceae (Klebsiella
pneumoniae, Klebsiella oxytoca and Escherichia coli) were character-
ized. The isolates harboured integrons containing the VIM-1
metallo-b-lactamase gene together with other resistance gene
cassettes. In particular, the CTX-M-2 gene was detected in four
of the K. pneumoniae isolates. The patient population was mostly
paediatric and characterized by severe underlying illnesses that
involved long-term hospitalization, major surgery and/or immu-
nosuppressive and broad-spectrum antibiotic therapy.
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Resistance to carbapenems may result from the presence of
metallo-b-lactamases (MBLs). These are zinc-dependent
b-lactam-hydrolysing enzymes with broad substrate speciﬁc-
ity that are not inhibited by clavulanic acid, sulbactam or
tazobactam. MBL genes can be chromosome- or plasmid-
borne, and are often located in integrons [1]. They are
usually found in nonfermenting Gram-negative bacteria and
are not frequent among the Enterobacteriaceae. However,
several recent studies have described both nonclinical [2] as
well as clinical isolates of MBL-producing enterobacteria
[2–6]. These included sporadic isolates, as well as isolates
from clonal epidemics and multiclonal endemic conditions
[6].
Carbapenem MICs are typically low and variable for MBL-
producing enterobacteria. This, together with the presence of
other b-lactamases, complicates their phenotypic detection in
routine tests. However, they can be readily detected with
speciﬁc phenotypic and molecular screening assays [7,8].
Between December 2005 and February 2008, several
carbapenem-resistant or intermediate enterobacterial isolates
were obtained from 12 hospitalized patients at Hospital Uni-
versitario La Paz, Madrid. Identiﬁcation and susceptibility
testing were conducted using the Wider (Francisco Soria
Melguizo SA, Madrid, Spain.) and Vitek 2 (bioMe´rieux, Barce-
lona, Spain.) automated systems. The isolates belonged
to three species (Klebsiella pneumoniae, Klebsiella oxytoca and
Escherichia coli). Single isolates from eight patients, and multi-
ple isolates from the other four patients, were obtained.
However, only one isolate per patient was analysed in detail.
One of the patients was an adult, hospitalized in the haema-
tology ward, whereas the others were children or infants
from the paediatric hospital. Patients were from different
wards and the isolates were well separated in time. Most
patients had severe illnesses involving major surgery and
long-term hospitalization (Table 1). Some of them had
repeated infections with different microorganisms, and all
had been receiving broad-spectrum antibiotic treatments. In
all cases, the infections were successfully treated, although
some patients had repeated septic episodes, which had to be
treated with a combination of antibiotics that included cipro-
ﬂoxacin. Clonal relatedness between K. pneumoniae isolates
was analysed using enterobacterial repetitive intergenic con-
sensus-PCR ﬁngerprinting with the primer ERIC2 [9] and
randomly ampliﬁed polymorphic DNA with the primers
OPI12 (5¢-AGAGGGCACA-3¢) and OPA18 (5¢-AGGTGAC
CGT-3¢) (Operon Technologies, Inc., Alameda, CA, USA).
Clonality was deﬁned using the criteria of Tenover et al.
[10]. The results obtained with these three primers were
consistent and indicated the presence of a major clone,
which included isolates 2, 3, 4, 8, 9, 10 and 11 (Tables 1
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and 2), and two additional clones, one represented by isolate
1 and another represented by isolate 7.
The susceptibility to carbapenems was variable among the
different isolates, even among isolates from a single patient.
For isolates with MIC values measured by microdilution
(‡1 mg/L of imipenem and/or meropenem), MBL production
was conﬁrmed using the double-disk synergy test with EDTA
and imipenem [11]. The MICs of imipenem, meropenem and
aztreonam were also determined using the E-test (AB Biodisk,
Solna, Sweden). MIC values measured by microdilution were
interpreted according to the CLSI guidelines [12]. When per-
forming the E-tests for isolates with MICs between 2 and
8 mg/L, the area of inhibition was so large that the effect of
EDTA could not be measured with the standard 0.5 MacFar-
land inoculum. A 5.0 MacFarland inoculum was used instead.
The MIC values measured in this way ranged from 1 to
>32 mg/L, but most of them were within the range of suscep-
tibility (£1 to £8 mg/L), although this range was determined
using standard inocula (Table 2). All the isolates were resistant
to most b-lactams, except aztreonam, and most of them were
also resistant to cotrimoxazol, tobramycin and gentamicin, but
remained susceptible to amikacin. Five K. pneumoniae isolates
were resistant to aztreonam (Table 2), which displayed syn-
ergy with clavulanic acid in double-disk tests, suggesting the
presence of extended-spectrum b-lactamases. Analysis by
PCR and DNA sequencing indicated that isolates 2, 3, 4 and
10, all belonging to the major clone, harboured the SHV-1
gene, which codes for a narrow-spectrum enzyme and the
CTX-M-2 gene. No extended-spectrum b-lactamase gene was
found in isolate 1, which was low-level resistant to aztreonam.
MBL genes were detected by PCR, using primers speciﬁc
for IMP or VIM genes [13], which are the most commonly
found types in Europe. All isolates carried a gene of the VIM
family of MBLs, whereas no genes of the IMP family were
detected. Sequencing identiﬁed the VIM-1 gene in two iso-
lates, one E. coli and one K. pneumoniae.
TABLE 1. Source of metallo-b-lactamases-producing isolates and patient data
Isolate Microorganism Sample Warda Underlying illness Age
1 Klebsiella pneumoniae Blood ICU CH Short bowel syndrome 6 months
2 Klebsiella pneumoniae Blood Hepatology CH Hepatic transplant 1 year
3 Klebsiella pneumoniae Blood Haemato-oncology CH Mucopolysaccharidosis type I (Hurler’s disease) 1 year
4 Klebsiella pneumoniae Ascitic ﬂuid ICU CH Peritonitis 7 months
5 Klebsiella oxytoca Bile Hepatology CH Hepatic transplant 2 years
6 Escherichia coli Urine Nephrology CH Bilateral moderate hydronephrosis; parieto-occipital plagiocephaly 1 year
7 Klebsiella pneumoniae Catheter Cardiovascular surgery CH Cardiofacial syndrome, tetralogy of Fallot 5 years
8 Klebsiella pneumoniae Urine ICU CH Intestinal transplant, short bowel syndrome 5 years
9 Klebsiella pneumoniae Fluid from gastrostomy Emergency room CH Pulmonary bronchodysplasia, gastrostomy 2 years
10 Klebsiella pneumoniae Blood Haematology GH Acute myeloid leukaemia 28 years
11 Klebsiella pneumoniae Bronchial aspirate ICU CH Premature birth, nephrocalcinosis intraventricular hemorrhage
grade 2, persistent ductus arteriosus
1 months
12 Escherichia coli Blood, urine Paediatric surgery CH Anal atresia with bilateral hydronephrosis 4 months
Each isolate was obtained from a different patient. One isolate per patient was included in the study.
aCH, Children’s Hospital; GH, General Hospital; ICU, intensive care unit
TABLE 2. Resistance phenotypes of MBL-producing enterobacterial isolates
Isolate
MIC (mg/L; microdilution) MIC (mg/L; E-test)
Resistance to non-b-lactam antibioticsMEM IMP CAZ CTX TZP FOX MEM IMP AZT
1a >8 8 >16 >16 >64/4 >16 1.5 1 8 SXT, GEN, TOB
2b,c 1 1 >64 >64 64 >64 4 2 256 SXT, TOB
3b,c 12 8 >64 >64 64 >64 1 1.5 64 SXT
4b,c 4 4 >16 >16 64/4 >16 >32 >32 12 SXT, TOB
5 2 4 >16 >16 >64/4 >16 2 16 0.047 SXT, GEN, TOB
6 £1 2 >16 >16 >64/4 >16 8 12 0.094 SXT, GEN, TOB
7d 4 4 >16 >16 >64/4 >16 1 12 0.094 SXT
8b >8 >8 >16 >16 >64/4 >16 4 16 0.047 SXT
9a £1 4 >16 >16 32/4 >16 1.5 2 0.047 SXT, GEN, TOB
10b,c 4 8 >16 >16 128 >64 >32 24 >256 SXT, GEN, TOB
11b >8 8 >16 >16 64/4 >16 >32 8 0.094 SXT
12 £1 2 >16 >8 64/4 >16 £1 2 0.12 SXT, GEN, TOB
Only one isolate per patient is shown.
MEM, meropenem; IMP, imipenem; AZT, aztreonam; CAZ, ceftazidime; CTX, cefotaxime; TZP, piperacillin/tazobactam; FOX, cefoxitine; SXT, trimethoprim–sulfamethoxazole;
GEN, gentamicin; TOB, tobramycin
a,dAddditional clones, identiﬁed by enterobacterial repetitive intergenic consensus-PCR ﬁngerprinting with ERIC2 and randomly ampliﬁed polymorphic DNA primers OPI12
and OPA18.
bIsolates representing a major clone.
cIsolates harbouring the blaSHV-1 and blaCTX-M-2 genes.
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PCR ampliﬁcation with the primers 5¢CS (5¢-GGC ATC
CAA GCA GCA AG-3¢) and 3¢CS (5¢-AAG CAG ACT TGA
CCT GAT-3¢) generated a 4.0-kb fragment from all
K. pneumoniae and E. coli isolates. Restriction analysis of the
PCR products with ClaI and SalI restriction enzymes
indicated that all isolates harboured the same element.
Sequencing of the 4.0-kb element from two isolates, one
K. pneumoniae and one E. coli, revealed that both of them
were identical to the class I integron In113 (GenBank acces-
sion number AY970968) [2]. The variable region of this
integron contained the genes: blaVIM-1-aacA4-dfrII-aadA1-catB
that would confer resistance to b-lactams, aminoglycosides,
cotrimoxazol and chloramphenicol. PCR analysis of the
K. oxytoca isolate revealed the presence of two amplicons, a
major one of 2 kb, and another one of >5 kb. PCR mapping
indicated that the two amplicons contained a blaVIM, as well
as aacA and aadA genes.
MBLs are uncommon among the Enterobacteriaceae, but
appear to be increasing in frequency and clinical relevance
as a result of their ability to spread geographically and to
disseminate between different clones and species [14,15].
Outbreaks of VIM-1-producing Enterobacteriaceae have been
described in Greece and Italy [3–5]. In Spain, they were ﬁrst
described in a large survey aiming to detect faecal carriage
[2], and also have been found in a clinical context [6]. The
report described an outbreak of monoclonal MBL-producing
K. pneumoniae that coexisted with multiclonal MBL-producing
Enterobacter cloacae in epidemics in a single hospital and sug-
gested an endemic status.
Most cases investigated in the present study belonged to a
group of patients with common characteristics. Except
for one adult, all patients were from the paediatric hospital.
A detailed examination of the clinical data indicated that the
causes of hospitalization were diverse, but all patients had
undergone major surgery, immunosuppressive treatments or
both. All patients had been treated with broad-spectrum anti-
biotics and, in some, the underlying condition (e.g. abscess,
malformation of the intestine or ureter) provided a physical
reservoir that might have supported the local growth of bac-
teria. This suggests that local reservoirs might be an impor-
tant factor because, even though the MICs of carbapenems
were in the range of susceptibility, large bacterial populations
might produce enough enzyme to overcome the antibiotic
treatment through an inoculum size effect [15,16].
Transparency Declaration
The authors declare no conﬂicting interests.
References
1. Boucher Y, Labbate M, Koenig JE, Stokes HW. Integrons: mobilizable
platforms that promote genetic diversity in bacteria. Trends Microbiol
2007; 15: 301–309.
2. To´rtola MT, Lavilla S, Miro´ E et al. First detection of a carbapenem-
hydrolyzing metalloenzyme in two enterobacteriaceae isolates in
Spain. Antimicrob Agents Chemother 2005; 49: 3492–3494.
3. Cagnacci S, Gualco L, Roveta S et al. Bloodstream infections caused
by multidrug-resistant Klebsiella pneumoniae producing the carbape-
nem-hydrolysing VIM-1 metallo-beta-lactamase: ﬁrst Italian outbreak.
J Antimicrob Chemother 2008; 61: 296–300.
4. Ikonomidis A, Tokatlidou D, Kristo I et al. Outbreaks in distinct
regions due to a single Klebsiella pneumoniae clone carrying a bla
VIM-1 metallo-b-lactamase gene. J Clin Microbiol 2005; 43: 5344–5347.
5. Psichogiou M, Tassios PT, Avlamis A et al. Ongoing epidemic of bla-
VIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective
survey. J Antimicrob Chemother 2008; 61: 59–63.
6. Tato M, Coque TM, Ruı´z-Garbajosa P et al. Complex clonal and plas-
mid epidemiology in the ﬁrst outbreak of Enterobacteriaceae infec-
tion involving VIM-1 metallo-beta-lactamase in Spain: toward
endemicity? Clin Infect Dis 2007; 45: 1171–1178.
7. Espedido BA, Thomas LC, Iredell JR. Metallo-beta-lactamase or
extended-spectrum beta-lactamase: a wolf in sheep’s clothing. J Clin
Microbiol 2007; 45: 2034–2036.
8. Pica˜o RC, Andrade SS, Nicoletti AG et al. Metallo-b-lactamase detec-
tion: comparative evaluation of double-disk synergy versus combined
disk tests for IMP, GIM, SIM, SPM or VIM-producing isolates. J Clin
Microbiol 2008; 46: 2028–2037.
9. Versalovic J, Schneid M, de Bruijn FJ, Lupski JR. Genomic ﬁngerprint-
ing of bacteria using repetitive sequence-based polymerase chain
reaction. Methods Mol Cell Biol 1994; 5: 25–40.
10. Tenover FC, Arbeit RD, Goering RV. How to select and interpret
molecular strain typing methods for epidemiological studies of bacte-
rial infections; a review for healthcare epidemiologists. Molecular typ-
ing working group of the Society for Healthcare Epidemiology of
America. Infect Control Hosp Epidemiol 1997; 18: 426–439.
11. Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge
test and the imipenem-EDTA double-disk synergy test for differenti-
ating metallo-beta-lactamase-producing isolates of Pseudomonas spp.
and Acinetobacter spp. J Clin Microbiol 2003; 41: 4623–4629.
12. CLSI. Performance standards for antimicrobial susceptibility testing.
16th informational supplement, M100–S16. Wayne, PA: CLSI, 2006.
13. Poirel L, Naas T, Nicolas D et al. Characterization of VIM-2, a carba-
penem-hydrolyzing metallo-beta-lactamase and its plasmid- and integ-
ron-borne gene from a Pseudomonas aeruginosa clinical isolate in
France. Antimicrob Agents Chemother 2000; 44: 891–897.
14. Jones RN, Deshpande LM, Bell JM et al. Evaluation of the contempo-
rary occurrence rates of metallo-beta-lactamases in multidrug-
resistant Gram-negative bacilli in Japan: report from the SENTRY
Antimicrobial Surveillance Program (1998-2002). Diagn Microbiol Infect
Dis 2004; 49: 289–294.
15. Walsh TR. The emergence and implications of metallo-beta-lactamases
in Gram-negative bacteria. Clin Microbiol Infect 2005; 6 (Suppl): 2–9.
16. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the
inoculum effect in tests with extended-spectrum b-lactamase-produc-
ing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45: 3548–
3554.
CMI Research Notes 183
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 179–199
